Core Viewpoint - The company, Xianjian Technology (01302.HK), has successfully completed the two-year follow-up of Phase II and Phase III clinical studies for its self-developed IBS absorbable drug-eluting coronary stent system, which will be presented at the TCT 2025 conference in the U.S. [1] Group 1 - The IBS coronary stent has completed two-year follow-ups for both Phase II and Phase III clinical studies [1] - The results of the Phase II clinical study's two-year imaging follow-up and the Phase III clinical study's two-year clinical endpoint follow-up will be announced at the TCT 2025 conference [1] - The presentation will be made by Professor Song Lei from the Fuwai Hospital of the Chinese Academy of Medical Sciences on behalf of Academician Gao Runlin and all researchers [1]
先健科技(01302.HK)：IBS®可吸收药物洗脱冠脉支架系统公布II期临床研究及III期临床研究两年随访结果